Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

SURMOUNT-J

Eli Lilly · Phase 3 · Completed · Enrollment 267

NCT04844918

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

96.052094.37
≥5%
92.11485.92
≥10%
82.891.3363.38
≥15%
≥20%
Show as table
Arm≥5%≥10%≥15%≥20%
10 Milligrams (mg) Tirzepatiden/rn/rn/rn/r
15 mg Tirzepatide96.05%92.11%82.89%n/r
Placebo20%4%1.33%n/r
10 mg Tirzepatide94.37%85.92%63.38%n/r

Not shown

  • 10 Milligrams (mg) Tirzepatide: endpoint not reported